ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FUM Futura Medical Plc

40.50
1.70 (4.38%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.70 4.38% 40.50 39.70 40.50 40.00 39.00 39.60 359,491 16:35:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -5.85M -0.0194 -20.62 120.28M
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 38.80p. Over the last year, Futura Medical shares have traded in a share price range of 24.10p to 67.00p.

Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £120.28 million. Futura Medical has a price to earnings ratio (PE ratio) of -20.62.

Futura Medical Share Discussion Threads

Showing 14301 to 14314 of 21225 messages
Chat Pages: Latest  573  572  571  570  569  568  567  566  565  564  563  562  Older
DateSubjectAuthorDiscuss
11/11/2022
22:20
Yet another feeble attempt at deflection by Petroc the proven liar. Fm71 was just a unblinded and uncontrolled medical device study. Not even full study design and all the full results have ever been fully published or fully peer reviewed. The only information and data anyone has seen is an RNS press release which gave some 'pooled' data but not all of it. Futura by their own admission has admitted it is exploiting the ˜least burdensome’ route of the De novo medical device pathway.



Devices are subject to weaker standards than drugs because they are regulated under a different law. The Medical Device Amendments of 1976 was intended to encourage innovation while allowing for a range of review standards based on risk, according to legal expert Richard A. Merrill. An array of corporate lobbying has since prompted Congress to ease regulations and make it easier for devices to get the FDA OK

Journalists need to scrutinize the claims.
Journalists have a responsibility to report this lack of evidence, but they often dont. Investigative journalist Jeanne Lenzer, who wrote a book about the under-regulated medical device industry, says more dogged reporting is needed: We really dont know what we are getting with many of these devices

Ninety-nine percent of devices never have to provide clinical data, thanks in part to the 2002 Medical Devices User Fee Act, which requires the FDA to use the least burdensome route

For the few devices subject to a scientific review, the quality standards are flimsy. Randomized controlled trials, the gold standard, are infrequent. Most studies are unblinded, and thus prone to bias. The FDA settles for loosely defined reasonable assurance that a device is safe and effective, versus its higher standard of substantial evidence for drugs, which require studies with comparison groups that didnt receive the same treatment. Thus, data that would never be sufficient to support the approval of a drug can result in the approval of a device used to treat the same condition, potentially diverting patients from effective drugs to less-effective devices.



When Futura describe the efficacy of MED3000, they are talking about improvement seen over the course of the treatment period known as 'change vs. baseline'.

Large improvements vs. baseline are common in the placebo groups in clinical trials of a wide range of conditions. This improvement is sometimes attributed to the 'placebo effect'

lbo
11/11/2022
19:02
Funny that LiarBO is harking back to 2021 again. That was when he predicted that the FDA trial would be a total failure! 'Lets see how fantastic the participants think it is over the 6 months of using it in the FDA study. The FDA obviously think the placebo effect will fall away over time when the participants know or realise they are just using a placebo gel. Presume in this FDA trail unlike in the Med2005 study they will be told or can at least now see in the public domain that the gel now contains no active vasodilator GTN drug and they are just studying an alcohol and water gel evaporating causing a cooling and warming effect?' Did you notice how LiarBO the stock basher twisted the truth into a lie there? He said 'the FDA obviously think that the placebo effect will fall away over time...' when in fact 'the FDA requested an additional 24 week confirmatory clinical study, known as “FM71” and the protocol was agreed with FDA.' They wanted to confirm that MED3000 was as efficacious over a longer period of time than in FM57. To everyone except LiarBO, the FDA believed the results of FM57 - that MED3000 worked in 60% of patients, and just needed to check it was as efficacious over a longer period of time. And guess what? It passed with flying colours, whatever the word twisting manipulator LiarBO says!
petroc
11/11/2022
18:19
ROFLMAO


loobrush - 30 Sep 2021 - 16:18:17 - 9987 of 13953

TRINITY DELTA UPDATE-VALUE 92p Sums it all up. The only fact in the research is that over £11m of the £12m will be burned through in losses for 2021 and 2022. It says first MED3000 launch expected during H22. Why so long away? The CE mark was awarded months ago. Trinity says emphasis still on prioritising longer-term value creation and brand building rather than near-term payments Why? With such a unique product with supposedly huge interest and a queue of partners lining up why can’t Futura demand both?

Then they say Clearly much depends on the marketing prowess of the relevant commercial partners but, assuming the clinical benefits seen in the trials are replicated consistently in a real-world setting? . So there it is. The whole report is based on one big assumption. And add in that all the Trinity sales forecasts are also based on the outdated Cello and IPSOS surveys from 2016 and on MED2002. Leaves shareholders reading Research based on a big assumption and based on very outdated and small market surveys on a different product

lbo
11/11/2022
17:52
Whoops !

The 94p valuation has sent LBO into overdrive,
Calm down dear boy!

loobrush
11/11/2022
17:17
Any cooling medical device lubricant/arousal gel can replicate all the same effects in the deficient Med3000 tests of rubbing, cooling sensation and placebo effect!

Also go back to David Ralph comments about MED2005 in this chat in Feb 2019 before Med2005 failed in its Phase 3 drug trial and their hand was forced to go down the route of getting the placebo gel approved as a Medical device.

Go to 6.45min in and you will hear him say many couples use lubrication and its not too much different from that’ But he could say that with MED2005 as it still contained GTN and had not yet failed so it was different. But now MED3000 with no drug is just rubbing on a cooling lubricant made just of alcohol, water and glycol





GSK also knew it was a lubricant having placebo effects all along even before it failed phase3. And now with the GTN ‘penile enhancer’ action removed after the phase 3 failure of Med2005/2002. Med3000 has nothing more then one action left. A lubricant with placebo effects when users are led to believe ‘ it works’ for ED.



No Goopy ED Gel in GSKs Futura




After Phase III Failure, UK Firm Pushes Placebo to Treat Erectile Dysfunction

lbo
11/11/2022
16:39
Come on Lbo let's have another lot of mis-information

Meanwhile just in case :-

Our main competitor - the little blue pill - has these problems

We all know what comes with Viagra don't we ?

Viagra may cause some unwanted side effects.

Side effects may include:

sensitivity to light
muscle aches
heartburn
nose bleeding
flushed skin
problems falling asleep
tingling in the arms, feet, legs, or hands
numbness in the arms, feet, legs, or hands
headache
diarrhea
heartburn
trouble differentiating between colors like blue and green
seeing a blue tinge on things

Viagra may also cause serious side effects that require immediate medical attention. Symptoms may include:

chest pain
fainting
blurred vision
severe, sudden loss of vision
ringing in ears
sudden loss of or decrease in hearing
dizziness
rash
burning during urination
itching during urination
shortness of breath that worsens
an erection that lasts longer than 4 hours and may be painful

Who would risk it - obviously Mr LBO does - he's dead keen

mikethebike4
11/11/2022
13:28
It was already admitted that the Dermasy vehicle and Voltaren vehicle gave similar results! LOL



‘TPR100 gave similar results to the gold standard, Voltarol 2% gel’



The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results. Consumer satisfaction with a topical product is based on subjective criteria such as how the product feels and how it is perceived on the skin. Therefore, appropriate questionnaires are of major importance for cosmetic products to assess the subjective perception not only of soothing and cooling effects but also of moistur- izing properties and fragrance.



A key element of Futura Medicals strategy is to reduce development risk through using well characterised existing agents that are reformulated with its proprietary DermaSys technology to create new products. This means intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect

lbo
11/11/2022
13:24
177 days is all it will take to a have similar product on the market via the 510k pathway. No clinical studies required for similar alcohol, water and glycol gels claiming to treat ED with evaporative cooling. And remember Futura still haven’t even shown that evaporative cooling is what is having any effect!



‘˜There is no evidence for the evaporative mode of action from the clinical trials. To show that the evaporation is what makes MED3000 work, you'd need to compare it to a non-evaporative gel’



‘˜This De Novo authorization will also allow subsequent devices of the same type and intended use to come to the market through the 510k pathway, which could enable the devices to get on the market faster’

De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing criteria called special controls that define the requirements related to labeling and performance testing. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for devices of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device

The average length of time for clearance under the traditional 510(k) pathway is 177 days,



a company must compare their product to one already cleared by the FDA and provide evidence that their product is substantially equivalent to the previously cleared (legally marketed) device. To be substantially equivalent, the product must meet criteria for the same intended use, have the same technology or (slightly) different technology but produces similar end results, and be safe and effective. Once pre-market clearance is received from the FDA the device can be distributed commercially immediately

lbo
11/11/2022
12:15
LBO

Just a reminder for sensible people :-

Our main competitor - the little blue pill - has these problems

We all know what comes with Viagra don't we ?

Viagra may cause some unwanted side effects.

Side effects may include:

sensitivity to light
muscle aches
heartburn
nose bleeding
flushed skin
problems falling asleep
tingling in the arms, feet, legs, or hands
numbness in the arms, feet, legs, or hands
headache
diarrhea
heartburn
trouble differentiating between colors like blue and green
seeing a blue tinge on things

Viagra may also cause serious side effects that require immediate medical attention. Symptoms may include:

chest pain
fainting
blurred vision
severe, sudden loss of vision
ringing in ears
sudden loss of or decrease in hearing
dizziness
rash
burning during urination
itching during urination
shortness of breath that worsens
an erection that lasts longer than 4 hours and may be painful

Who would risk it - obviously Mr LBO does - he's dead keen

mikethebike4
11/11/2022
09:21
Don’t forget to read the clear disclaimers and assumptions given by Trinity! Unlike the rampers! LOL

‘the company covered in the research notes pays us a set fee in order for this research to be made available (technically known as the “issuer pays” model)’

‘Whilst every reasonable effort is made to ensure that the information in the research is correct, this cannot be guaranteed’

‘Trinity Delta does not make recommendations. Accordingly, we do not publish records of our past recommendations. Where a fair value price is given in a research note this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price’

‘given limited disclosure of precise terms in Europe (which includes multiple revenue layers based on various accounting practices)’

‘limited visibility on precise launch timings and details on likely revenue and cost recognition in Europe, in addition to as yet unknown and unpredictable US deal terms, we do not currently include any potential MED3000 revenues in our Profit and Loss forecasts’

Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

lbo
11/11/2022
09:04
Excellent broker note out



Launches imminent in the europe and uk areas


Tone indicates shares potentially worth much much more than 94p


Also reminds us that Cooper did at home studies of their own with similar excellent results



Exciting times ahead

j777j
10/11/2022
21:12
And what will happen when the money doesn’t start rolling in as has happened with PET500, TPR100 and CSD500? Will shareholders see 9.4p again? Even at 9p Lombard could still continue to dump shares and be still in the money as they got 35.7m shares at 7p in the October 2018 placing and another 21.875m shares at 8p in December 2019 placing.

To quote mike ‘ Do you have any idea of how long shareholders have been using these words’

LOL

Just like there was still no sign of any revenue in the last Futura results. Even after the RNS said there was ann‘initial upfront payment’ from Cooper!?

I too like mike ‘loath to give any credence’ to the ‘smoke screen’ ROFLMAO


mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141

Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says

mikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141

Company is massively over valued if you go by 'concrete' results !

mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141

I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.
I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares
Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !

mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591

"A couple of decent deals and will be back off to the races."
Do you have any idea of how long shareholders have been using these words

mikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591

As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated.
All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day!

mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713

why should it be any different this time when you've still got the same useless lot running the show

mikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641

I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-life
And where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remuneration
I just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick

lbo
10/11/2022
20:54
Thanks for posting the 94p Trinity valuation loobrush. Once the money starts rolling in 94p will look cheap ;-)
broomrigg
10/11/2022
19:51
On the cusp of MED3000 commercialisation

TRINITY DELTA VALUATION 94p

Please find attached our Update report on Futura Medical, a R&D-driven small pharma with a novel proprietary transdermal delivery system, DermaSys, and lead programme, MED3000 in erectile dysfunction, following a number of key events this year.

Download full report here (mobile friendly).
Symbol FUM (AIM London)
Price 40.2p (£115.6m)
Date 10 November 2022
During 2022 Futura Medical successfully delivered on several key MED3000 related events, including the highly positive FM71 longer-term clinical data, which are needed to enter the US market and importantly reinforced MED3000’s differentiated and rapid onset of action. In addition, a number of commercial deals were executed, notably the European and UK deal with Cooper Consumer Health. The next steps are EU launches (due to start during H123), FDA marketing clearance (potentially by end Q123), and securing a US partner. These should be the final elements in converting MED3000 into a revenue generating OTC product for ED, transforming Futura Medical’s prospects. Pending visibility on both US and European launches, our updated model conservatively does not include any near-term MED3000 related revenues. Our Futura Medical valuation is now £270m, equivalent to 94p per share.

loobrush
Chat Pages: Latest  573  572  571  570  569  568  567  566  565  564  563  562  Older

Your Recent History

Delayed Upgrade Clock